首页> 外文OA文献 >Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities
【2h】

Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities

机译:结核病诊断和生物标志物:需求,挑战,最新进展和机遇

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Tuberculosis is unique among the major infectious diseases in that it lacks accurate rapid point-of-care diagnostic tests. Failure to control the spread of tuberculosis is largely due to our inability to detect and treat all infectious cases of pulmonary tuberculosis in a timely fashion, allowing continued Mycobacterium tuberculosis transmission within communities. Currently recommended gold-standard diagnostic tests for tuberculosis are laboratory based, and multiple investigations may be necessary over a period of weeks or months before a diagnosis is made. Several new diagnostic tests have recently become available for detecting active tuberculosis disease, screening for latent M. tuberculosis infection, and identifying drug-resistant strains of M. tuberculosis. However, progress toward a robust point-of-care test has been limited, and novel biomarker discovery remains challenging. In the absence of effective prevention strategies, high rates of early case detection and subsequent cure are required for global tuberculosis control. Early case detection is dependent on test accuracy, accessibility, cost, and complexity, but also depends on the political will and funder investment to deliver optimal, sustainable care to those worst affected by the tuberculosis and human immunodeficiency virus epidemics. This review highlights unanswered questions, challenges, recent advances, unresolved operational and technical issues, needs, and opportunities related to tuberculosis diagnostics
机译:结核病在主要的传染病中是独特的,因为它缺乏准确的快速即时诊断服务。无法控制结核病的蔓延在很大程度上是由于我们无法及时发现和治疗所有肺结核感染病例,从而导致结核分枝杆菌继续在社区内传播。当前推荐的针对结核病的金标准诊断测试是基于实验室的,在做出诊断之前的几周或几个月内,可能需要进行多次检查。最近有几种新的诊断测试可用于检测活动性结核病,筛查潜在的结核分枝杆菌感染以及鉴定结核分枝杆菌的耐药菌株。但是,在强大的即时检验方面取得的进展有限,新型生物标志物的发现仍然具有挑战性。在缺乏有效的预防策略的情况下,全面控制结核病需要较高的早期病例发现率和随后的治愈率。早期病例检测取决于测试的准确性,可及性,成本和复杂性,还取决于政治意愿和资助者的投资,以便为受结核病和人类免疫缺陷病毒流行病影响最严重的人提供最佳,可持续的护理。这篇综述重点介绍了与结核病诊断相关的未解决的问题,挑战,最新进展,未解决的运营和技术问题,需求以及机会

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号